Abstract
Tyrosine kinase inhibitor (TKI)-combined chemotherapy has become the standard option in pediatric Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) treatment. Additionally, hematopoietic cell transplantation (HCT) in the first remission is no longer an absolute indication. However, pediatric Ph+ALL remains refractory leukemia, with a disease-free survival rate of approximately 60% for patients without HCT in the first remission due to treatment-related death or relapse after chemotherapy. Further outcome improvement will require an intensified targeted therapy with second- or third-generation TKIs or less toxic immunotherapies, as well as improved safety, with reduced conventional chemotherapy. Continuous attention to these issues in clinical trials will change pediatric Ph+ALL from intractable to manageable leukemia in the future.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: [Rinsho ketsueki] The Japanese journal of clinical hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
